Endometriosis Treatment Market, By Treatment Type (Hormone Therapy and Pain Medication), By Drug Class, By Distribution Channel, By Route Of Administration, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5201
|
Published Date
May 2026
|
Pages
387
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Endometriosis Treatment Market size was valued at US$ 1,971.92 Million in 2025, expanding at a CAGR of 11.32% from 2026 to 2033.
Endometriosis treatment refers to the range of medical and supportive interventions used to manage a condition in which tissue similar to the uterine lining grows outside the uterus. This disorder can cause pelvic pain, painful menstrual cycles, fatigue, and fertility-related complications. Treatment approaches aim to reduce symptoms, improve daily functioning, and support reproductive health outcomes. Common options include hormone-based therapies, pain management medications, minimally invasive surgical procedures, and fertility treatments. Clinicians typically tailor treatment plans based on symptom severity, age, lifestyle factors, and pregnancy considerations to ensure effective long-term disease management and improved quality of life.
The condition is receiving increasing global healthcare attention as awareness of women’s reproductive health disorders continues to rise. According to the World Health Organization, approximately 190 million women and girls of reproductive age are affected by endometriosis worldwide, highlighting the significant need for improved diagnosis and treatment services. The National Health Service recognizes endometriosis as one of the leading causes of chronic pelvic pain and fertility-related complications among women. In addition, the Australian Government Department of Health has introduced national action programs aimed at improving early diagnosis, awareness, and clinical management of endometriosis.
Endometriosis Treatment Market- Market Dynamics
Increasing awareness programs and government-led women’s health initiatives to support treatment adoption
Growing awareness campaigns and public healthcare initiatives are becoming a key factor supporting the development of the endometriosis treatment sector, as more women are being diagnosed at earlier stages and seeking timely medical care. Governments across several countries are increasing support for education, diagnosis, and specialist care services related to chronic gynecological conditions. The Australian Government Department of Health has committed more than AUD 127 million under the National Action Plan for Endometriosis to strengthen awareness, clinical management, and research initiatives. In addition, National Health Service England has expanded women’s health strategies aimed at reducing diagnostic delays and improving access to pelvic pain services.
Meanwhile, Health Canada continues to support women’s reproductive health education and community healthcare programs. From an industry perspective, Bayer is expanding its women’s healthcare portfolio through hormone therapy research and gynecology-focused treatment solutions. Additionally, AbbVie is strengthening its reproductive health research efforts focused on chronic inflammatory and hormone-related conditions.
Endometriosis Treatment Market- Segmentation Analysis:
The Global Endometriosis Treatment Market is segmented on the basis of Treatment Type, Drug Class, Distribution Channel, Route of Administration, and Region.
According to treatment type, the market is divided into two categories: hormone therapy and pain medication. Hormone therapy accounts for a significant share in the segment as it directly targets hormonal imbalances responsible for abnormal tissue growth. This approach is widely used for long-term symptom management, as it helps reduce pelvic pain, control lesion progression, and improve overall patient comfort. From a clinical development perspective, Pfizer Inc. continues to advance research in hormone-based therapies for reproductive health disorders, focusing on improved tolerability and better treatment outcomes. In addition, Gedeon Richter is expanding its gynecology portfolio with hormone-based solutions aimed at more effective management of endometriosis-related symptoms.
Under drug class segmentation, the market is divided into three categories: oral contraceptives, NSAIDs, and gonadotropin-releasing hormone (GnRH) therapies. GnRH therapy is expected to remain highly influential in endometriosis management due to its ability to regulate hormone levels and reduce estrogen-driven tissue growth, which is a key driver of symptoms. It is typically prescribed for patients with moderate to severe conditions when first-line pain relief options are insufficient. This treatment area is continuously evolving through pharmaceutical innovation aimed at improving safety profiles and long-term patient comfort. Takeda Pharmaceutical Company is actively engaged in developing advanced therapies for gynecology and hormone-related disorders, strengthening its reproductive health pipeline. Similarly, Novartis continues to invest in research programs focused on hormone regulation and chronic inflammatory conditions.
Endometriosis Treatment Market- Geographical Insights
In terms of regional distribution, the market shows varying growth patterns across regions due to differences in healthcare awareness, diagnostic accessibility, and women’s health support systems. North America holds a prominent share in this market, supported by strong healthcare infrastructure, higher awareness of reproductive health disorders, and sustained investment in advanced gynecological research. The region benefits from early diagnosis initiatives, widespread access to minimally invasive surgical procedures, and the availability of hormone-based and fertility-related therapies across hospitals and specialty clinics. According to the World Health Organization, endometriosis affects nearly 190 million women and girls of reproductive age globally, highlighting the increasing need for structured treatment systems and awareness programs.
The National Institutes of Health reports that endometriosis affects approximately 5% to 10% of women in the United States, supporting continued investment in diagnostic and therapeutic research. In addition, the Eunice Kennedy Shriver National Institute of Child Health and Human Development recognizes endometriosis as one of the most common gynecological disorders associated with chronic pain and infertility, encouraging long-term clinical studies and treatment innovation. From a commercial perspective, AbbVie continues to advance research in women’s health and hormone-based therapies, while Pfizer Inc. is expanding its focus on inflammatory and reproductive health treatment innovation.
Germany Endometriosis Treatment Market- Country Insights
In terms of healthcare development, Germany follows a structured and research-driven approach to endometriosis management, supported by strong hospital systems and coordinated national clinical frameworks. According to the Federal Ministry of Health (Germany), government-backed initiatives have recently allocated around €10 million to women’s health research, with endometriosis identified as a priority area for improving diagnosis and treatment pathways. The Robert Koch Institute also plays a key role in chronic disease surveillance and national health data collection, helping strengthen understanding of gynecological conditions across populations.
In addition, the Federal Statistical Office of Germany reports a rise in hospital-based treatment cases for endometriosis in recent years, indicating improved detection rates and greater medical attention. From a clinical and industry perspective, Bayer continues to contribute to reproductive health innovation through hormone-based therapies and women’s healthcare solutions. Overall, these developments reflect a healthcare ecosystem where public funding, national health monitoring, and pharmaceutical innovation work together to improve early diagnosis, patient access to care, and long-term treatment outcomes for endometriosis patients in Germany.
Endometriosis Treatment Market- Competitive Landscape:
The endometriosis treatment market is developing steadily as pharmaceutical companies, healthcare providers, and biotechnology firms focus on improving women’s health outcomes through advanced therapies and supportive care solutions. Industry participants are increasingly emphasizing hormone-based therapies, non-hormonal drug development, minimally invasive surgical approaches, and fertility-related treatments to address long-standing unmet medical needs. Treatment access is expanding through hospitals, specialty clinics, retail pharmacies, and digital healthcare platforms. Key companies shaping this market include AbbVie, Bayer, Pfizer Inc., Gedeon Richter, and ObsEva, which continue to strengthen reproductive health research and improve treatment accessibility globally.
Industry stakeholders are increasingly prioritizing patient-centric therapies, long-term symptom management, and strategic collaborations to advance innovation in gynecological care. Many organizations are investing in clinical research, digital health monitoring tools, and precision medicine approaches to enhance diagnosis and treatment outcomes. For example, National Health Service England approved the rollout of a daily oral relugolix combination therapy designed to support more convenient home-based management of endometriosis. Meanwhile, Maipl Therapeutics collaborated with Endosure Inc. to advance clinical development of non-hormonal treatment solutions, reflecting growing interest in less invasive and more personalized care approaches.
Recent Developments
- In March 2026, EndoCyclic Therapeutics received U.S. FDA clearance to initiate human clinical trials for ENDO-205, a non-hormonal investigational therapy targeting endometriosis lesions directly. This development highlights increasing focus on precision-based and non-surgical treatment alternatives in women’s healthcare.
- In September 2025, Gesynta Pharma received approval from UK health authorities to begin a Phase II clinical study of vipoglanstat in patients with endometriosis. The study aims to evaluate the safety and efficacy of the investigational therapy across multiple European clinical sites.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ENDOMETRIOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- AstraZeneca
- Bayer AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Zydus Lifesciences Ltd.
- Astellas Pharma Inc.
- Gesynta Pharma
- Gedeon Richter Plc.
- Takeda Pharmaceutical Company Limited
- Kissei Pharmaceutical Co., Ltd.
- Merck & Co., Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Ferring Pharmaceuticals
- EndoCyclic Therapeutics
- Myovant Sciences
- Ipsen Pharma
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Neurocrine Biosciences Inc.
- Evotec SE
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033
- Hormone Therapy
- Pain Medication
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Oral Contraceptive
- NSAIDs
- Gonadotropin Releasing Hormone
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacy
- Hospital Pharmacy
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Injectable
- Oral
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Endometriosis Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Endometriosis Treatment Market Snippet by Treatment Type
2.1.2. Endometriosis Treatment Market Snippet by Drug Class
2.1.3. Endometriosis Treatment Market Snippet by Distribution Channel
2.1.4. Endometriosis Treatment Market Snippet by Route Of Administration
2.1.5. Endometriosis Treatment Market Snippet by Country
2.1.6. Endometriosis Treatment Market Snippet by Region
2.2. Competitive Insights
3. Endometriosis Treatment Key Market Trends
3.1. Endometriosis Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Endometriosis Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Endometriosis Treatment Market Opportunities
3.4. Endometriosis Treatment Market Future Trends
4. Endometriosis Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Endometriosis Treatment Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Endometriosis Treatment Market Landscape
6.1. Endometriosis Treatment Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Endometriosis Treatment Market – By Treatment Type
7.1. Overview
7.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
7.1.2. Hormone Therapy
7.1.3. Pain Medication
7.1.4. Others
8. Endometriosis Treatment Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2025 & 2033 (%)
8.1.2. Oral Contraceptive
8.1.3. NSAIDs
8.1.4. Gonadotropin Releasing Hormone
8.1.5. Others
9. Endometriosis Treatment Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
9.1.2. Retail Pharmacy
9.1.3. Hospital Pharmacy
9.1.4. Others
10. Endometriosis Treatment Market – By Route Of Administration
10.1. Overview
10.1.1. Segment Share Analysis, By Route Of Administration, 2025 & 2033 (%)
10.1.2. Injectable
10.1.3. Oral
10.1.4. Others
11. Endometriosis Treatment Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Endometriosis Treatment Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Endometriosis Treatment Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.17. Denmark
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.17.4. Denmark Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.17.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.17.6. Denmark Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.3.18. Rest of Europe
11.3.18.1. Overview
11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.3.18.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.3.18.6. Rest of the Europe Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Endometriosis Treatment Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.16. Taiwan
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Taiwan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.16.4. Taiwan Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.16.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.16.6. Taiwan Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.17. Vietnam
11.4.17.1. Overview
11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.17.3. Vietnam Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.17.4. Vietnam Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.17.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.17.6. Vietnam Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.4.18. Rest of APAC
11.4.18.1. Overview
11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.18.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.4.18.6. Rest of APAC Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Endometriosis Treatment Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Endometriosis Treatment Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.14. Iran
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Iran Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.14.4. Iran Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.14.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.14.6. Iran Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.15. Qatar
11.6.15.1. Overview
11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.15.3. Qatar Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.15.4. Qatar Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.15.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.15.6. Qatar Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
11.6.16. Rest of MEA
11.6.16.1. Overview
11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.16.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
11.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2020 - 2033 (US$ Million)
11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
11.6.16.6. Rest of MEA Market Size and Forecast, By Route Of Administration, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Endometriosis Treatment Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. AbbVie Inc.
12.2.2. AstraZeneca
12.2.3. Bayer AG
12.2.4. Pfizer Inc.
12.2.5. Sanofi
12.2.6. Teva Pharmaceutical Industries Ltd.
12.2.7. Zydus Lifesciences Ltd.
12.2.8. Astellas Pharma Inc.
12.2.9. Gesynta Pharma
12.2.10. Gedeon Richter Plc.
12.2.11. Takeda Pharmaceutical Company Limited
12.2.12. Kissei Pharmaceutical Co., Ltd.
12.2.13. Merck & Co., Inc.
12.2.14. Eli Lilly and Company
12.2.15. Johnson & Johnson
12.2.16. Ferring Pharmaceuticals
12.2.17. EndoCyclic Therapeutics
12.2.18. Myovant Sciences
12.2.19. Ipsen Pharma
12.2.20. Abbott Laboratories
12.2.21. Sun Pharmaceutical Industries Ltd.
12.2.22. Neurocrine Biosciences Inc.
12.2.23. Evotec SE
12.2.24. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ENDOMETRIOSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie Inc.
- AstraZeneca
- Bayer AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Zydus Lifesciences Ltd.
- Astellas Pharma Inc.
- Gesynta Pharma
- Gedeon Richter Plc.
- Takeda Pharmaceutical Company Limited
- Kissei Pharmaceutical Co., Ltd.
- Merck & Co., Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Ferring Pharmaceuticals
- EndoCyclic Therapeutics
- Myovant Sciences
- Ipsen Pharma
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Neurocrine Biosciences Inc.
- Evotec SE
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033
- Hormone Therapy
- Pain Medication
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2020 - 2033
- Oral Contraceptive
- NSAIDs
- Gonadotropin Releasing Hormone
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033
- Retail Pharmacy
- Hospital Pharmacy
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033
- Injectable
- Oral
- Others
GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
